Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis

@article{Wang2012EffectOL,
  title={Effect of long‐acting beta‐agonists on the frequency of COPD exacerbations: a meta‐analysis},
  author={J. Wang and B. Nie and W. Xiong and Y. Xu},
  journal={Journal of Clinical Pharmacy and Therapeutics},
  year={2012},
  volume={37}
}
  • J. Wang, B. Nie, +1 author Y. Xu
  • Published 2012
  • Medicine
  • Journal of Clinical Pharmacy and Therapeutics
  • What is Known and Objective:  Inhaled long‐acting beta‐agonists have been licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late 1990s, and they improve lung function and symptoms of dyspnoea. However, the evidence that long‐acting beta‐agonists alone can reduce the rate of COPD exacerbations is not conclusive. This meta‐analysis was performed to evaluate their effect on the frequency of exacerbations. 
    Indacaterol for the treatment of chronic obstructive pulmonary disease
    7
    Pharmacotherapies for COPD
    30
    Is ‘GOLD’ standard for the management of COPD in clinical practice?
    10

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 46 REFERENCES
    Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.
    2878